Rankings

Market Cap
Revenue
Operating Income
CapEx
Total Assets
Net Assets
Cash on Hand

Sectors

Technology
Healthcare
Financial Services
Consumer Cyclical
Communication Services
Industrials
Consumer Defensive
Energy
Basic Materials
Real Estate
Utilities

Pages

Home
Earnings Calendar
All Sectors
Terms
Privacy

© 2026 Market Cap Arena. All rights reserved.v1.2.29

RVMD Q4 2018 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$19B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M

Gross Profit

$10M100.0% margin

Operating Income

-$12M-112.8% margin

Net Income

-$11M-109.6% margin

EPS (Diluted)

$-0.31

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$281,000

Balance Sheet

Total Assets

$171M

Total Liabilities

$74M

Stockholders' Equity

$97M

Cash & Equivalents

$70M

← FY 2018 All Quarters Q1 2019 →